Anticonvulsant effect of polyunsaturated fatty acids in rats, using the cortical stimulation model.
Recent studies have shown that long-chain polyunsaturated fatty acids can prevent cardiac arrhythmias, attributed to the reduction in excitability of cardiomyocytes, owing mainly to a shift in hyperpolarizing direction of the inactivation curves of both Na+ and Ca2+ currents and to a slowed recovery from inactivation. Qualitatively similar effects of polyunsaturated fatty acids on inactivation parameters have been observed in freshly isolated hippocampal neurons. Since the same effects are presumed to underlie the action of some established anticonvulsant drugs, polyunsaturated fatty acids might have an anticonvulsant action as well. We have investigated this for eicosapentaenoic acid, docosahexaenoic acid, linoleic acid and oleic acid, employing cortical stimulation in rats, a seizure model allowing the determination of the full anticonvulsant effect-time profile in freely moving, individual animals. I.v. infusion of 40 micromol of eicosapentaenoic acid or docosahexaenoic acid over a period of 30 min, modestly increased the threshold for localized seizure activity after 6 h by 73 +/- 13 microA (mean +/- S.E.M.; n = 7) and 77 +/- 17 microA (n = 7), respectively, and the threshold for generalized seizure activity by 125 +/- 20 and 130 +/- 19 microA, respectively (P < 0.001). The thresholds remained elevated for 6 h after infusion, but returned to baseline the next day. Free plasma concentrations in rats treated with eicosapentaenoic acid or docosahexaenoic acid, averaged 5.7 +/- 1.6 microM (n = 4) for eicosapentaenoic acid and 12.9 +/- 1.8 microM (n = 5) for docosahexaenoic acid at the end of infusion, but declined to undetectable levels within 3 h. Linoleic acid and oleic acid were less effective. Possible mechanisms for the modest anticonvulsant effect but of long duration with the polyunsaturated fatty acids are discussed.
Voskuyl
R A
RA
Department of Physiology, Leiden University, The Netherlands.
Vreugdenhil
M
M
Kang
J X
JX
Leaf
A
A
D000818:Animals; D004195:Disease Models, Animal; D004281:Docosahexaenoic Acids / Q000627:therapeutic use; D004558:Electric Stimulation; D005231:Fatty Acids, Unsaturated / Q000627:therapeutic use*; D019787:Linoleic Acid / Q000627:therapeutic use; D008297:Male; D019301:Oleic Acid / Q000627:therapeutic use; D017063:Outcome Assessment, Health Care; D051381:Rats; D017208:Rats, Wistar; D012640:Seizures / Q000188:drug therapy*; D014635:Valproic Acid / Q000627:therapeutic use
D005231:Fatty Acids, Unsaturated; D004281:Docosahexaenoic Acids; D019301:Oleic Acid; D014635:Valproic Acid; D019787:Linoleic Acid